1
|
Kelly KM, Friedberg JW. Classic Hodgkin Lymphoma in Adolescents and Young Adults. J Clin Oncol 2024; 42:653-664. [PMID: 37983570 DOI: 10.1200/jco.23.01799] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2023] [Revised: 08/28/2023] [Accepted: 09/20/2023] [Indexed: 11/22/2023] Open
Abstract
Hodgkin lymphoma (HL) represents one of the more common cancers occurring in adolescent and young adults (AYAs) age 15-39 years. Despite a generally high cure rate, age-related differences in HL biology and the optimal therapeutic approaches including supportive care and risks for long-term adverse effects in the AYA population remain understudied. After an overview of HL epidemiology and biology in the AYA population, this review will cover frontline pediatric and adult treatment approaches. Recently completed and ongoing studies will foster harmonization of risk group definition and trial eligibility criteria across the AYA spectrum, enabling more rapid progress. In addition to treatment approaches, an evolving holistic care approach to AYA HL will result in enhanced understanding of unique challenges, and continued improved short- and long-term outcome for these patients.
Collapse
Affiliation(s)
- Kara M Kelly
- Department of Pediatrics, Roswell Park Comprehensive Cancer Center., Buffalo, NY
- Division of Pediatric Hematology/Oncology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY
- Pediatric Hematology/Oncology, Oishei Children's Hospital, Buffalo, NY
| | | |
Collapse
|
3
|
Brice P, de Kerviler E, Friedberg JW. Classical Hodgkin lymphoma. Lancet 2021; 398:1518-1527. [PMID: 33493434 DOI: 10.1016/s0140-6736(20)32207-8] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 06/11/2020] [Accepted: 10/15/2020] [Indexed: 11/29/2022]
Abstract
Classical Hodgkin lymphoma is one of the more frequent lymphomas and is generally considered a highly curable disease with standard first-line chemotherapy and radiotherapy in some cases. Despite these outstanding results, major problems remain unresolved. First, there are still patients who will not be cured with front-line regimens and, second, many patients who are cured of classical Hodgkin lymphoma continue to die prematurely due to the late toxic effects of their therapy. Because the median age of patients with classical Hodgkin lymphoma is in the mid-30s, the disease's impact on the number of years lost from productive life is remarkable. In recent years, the gold standard of chemotherapy (often combined with radiotherapy) has changed, with the approval of immunotherapy mostly in relapse settings.
Collapse
Affiliation(s)
- Pauline Brice
- Department of Oncohaematology, Hôpital saint Louis APHP, Université Paris 7, Paris, France.
| | - Eric de Kerviler
- Department of Radiology, Hôpital saint Louis APHP, Université Paris 7, Paris, France
| | | |
Collapse
|
4
|
Roma S, Carpen L, Raveane A, Bertolini F. The Dual Role of Innate Lymphoid and Natural Killer Cells in Cancer. from Phenotype to Single-Cell Transcriptomics, Functions and Clinical Uses. Cancers (Basel) 2021; 13:cancers13205042. [PMID: 34680190 PMCID: PMC8533946 DOI: 10.3390/cancers13205042] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/05/2021] [Accepted: 10/06/2021] [Indexed: 02/07/2023] Open
Abstract
Simple Summary Innate lymphoid cells (ILCs), a family of innate immune cells including natural killers (NKs), play a multitude of roles in first-line cancer control, in escape from immunity and in cancer progression. In this review, we summarize preclinical and clinical data on ILCs and NK cells concerning their phenotype, function and clinical applications in cellular therapy trials. We also describe how single-cell transcriptome sequencing has been used and forecast how it will be used to better understand ILC and NK involvement in cancer control and progression as well as their therapeutic potential. Abstract The role of innate lymphoid cells (ILCs), including natural killer (NK) cells, is pivotal in inflammatory modulation and cancer. Natural killer cell activity and count have been demonstrated to be regulated by the expression of activating and inhibitory receptors together with and as a consequence of different stimuli. The great majority of NK cell populations have an anti-tumor activity due to their cytotoxicity, and for this reason have been used for cellular therapies in cancer patients. On the other hand, the recently classified helper ILCs are fundamentally involved in inflammation and they can be either helpful or harmful in cancer development and progression. Tissue niche seems to play an important role in modulating ILC function and conversion, as observed at the transcriptional level. In the past, these cell populations have been classified by the presence of specific cellular receptor markers; more recently, due to the advent of single-cell RNA sequencing (scRNA-seq), it has been possible to also explore them at the transcriptomic level. In this article we review studies on ILC (and NK cell) classification, function and their involvement in cancer. We also summarize the potential application of NK cells in cancer therapy and give an overview of the most recent studies involving ILCs and NKs at scRNA-seq, focusing on cancer. Finally, we provide a resource for those who wish to start single-cell transcriptomic analysis on the context of these innate lymphoid cell populations.
Collapse
|
5
|
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 2018; 132:1013-1021. [PMID: 30049811 DOI: 10.1182/blood-2018-01-827246] [Citation(s) in RCA: 70] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Accepted: 06/20/2018] [Indexed: 11/20/2022] Open
Abstract
A negative interim positron emission tomography/computerized tomography (PET/CT) after 1 to 3 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with newly diagnosed, nonbulky stage I or II Hodgkin lymphoma (HL) predicts a low relapse rate. This phase 2 trial was designed to determine if a population of patients with early-stage disease can be treated with short-course ABVD without radiation therapy (RT) on the basis of a negative interim PET/CT, thereby limiting the risks of treatment. Between 15 May 2010 and 21 February 2013, 164 previously untreated patients with nonbulky stage I/II HL were enrolled, and 149 were included in the final analysis. Patients received 2 cycles of ABVD followed by PET. Deauville scores 1 to 3 were negative (≤ liver uptake) based on central review. PET- patients received 2 more cycles of ABVD, and PET+ patients received 2 cycles of dose-intense bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escalated BEACOPP) plus 3060-cGy involved-field RT. The primary objective was to determine 3-year progression-free survival (PFS) for the PET- group. One hundred thirty-five patients (91%) were interim PET-, and 14 patients (9%) were PET+ With median follow-up time of 3.8 years, the estimated 3-year PFS was 91% for the PET- group and 66% for the PET+ group (hazard ratio, 3.84; 95% confidence interval, 1.50-9.84; P = .011). There was 1 death as a result of suicide. Four cycles of ABVD resulted in durable remissions for a majority of patients with early-stage nonbulky HL and a negative interim PET. This trial was registered at www.clinicaltrials.gov as #NCT01132807.
Collapse
|
6
|
André MPE, Federico M, Fortpied C, Girinsky T, Meignan M, Raemaekers J. Reply to J.A. Vargo et al, H.J.A. Adams et al, E. Hindié et al, and S. Kothari et al. J Clin Oncol 2017; 35:2853-2854. [PMID: 28682682 DOI: 10.1200/jco.2017.74.0068] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Marc P E André
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Massimo Federico
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Catherine Fortpied
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Théodore Girinsky
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Michel Meignan
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| | - John Raemaekers
- Marc P.E. André, Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium; Massimo Federico, University of Modena and Reggio Emilia, Modena, Italy; Catherine Fortpied, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Théodore Girinsky, Institut Gustave Roussy, Villejuif, France; Michel Meignan, Henri Mondor University Hospitals, Créteil, France; and John Raemaekers, Radboud University Medical Center, Nijmegen, the Netherlands
| |
Collapse
|